Genzyme, Third Rock Bet $35 Million on Gene Therapy Developer (Bloomberg)
March 12th, 2010
March 12 (Bloomberg) — Genzyme Inc. ’s investment arm and Third Rock Ventures , a Boston venture capital firm, are putting $35 million into closely held Genetix Pharmaceuticals, a gene therapy developer whose technology saved the lives of two French boys with a rare brain disease last year.
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)